Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer

To the best of our knowledge, no published reports have examined the significance of additional immune checkpoint inhibitors in treating malignancies, including lung cancer. Therefore, the present study aimed to examine the efficacy and feasibility of adding atezolizumab to carboplatin and etoposide...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuda, Takeshi, Imai, Hisao, Nagai, Yoshiaki, Umeda, Yukihiro, Shiono, Ayako, Shiihara, Jun, Yamaguchi, Ou, Mouri, Atsuto, Kaira, Kyoichi, Ishizuka, Tamotsu, Taniguchi, Hirokazu, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932630/
https://www.ncbi.nlm.nih.gov/pubmed/36817046
http://dx.doi.org/10.3892/ol.2023.13696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932630/
https://www.ncbi.nlm.nih.gov/pubmed/36817046
http://dx.doi.org/10.3892/ol.2023.13696

Ejemplares similares